Tirtha Chakraborty

Biogen (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

18h-index2.9kcitations48works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CRISPR and Genetic Engineering(10), Immune Cell Function and Interaction(10), CAR-T cell therapy research(10), MicroRNA in disease regulation(6), Advanced biosensing and bioanalysis techniques(6)

Publications48 total

A Human Genetics Framework for De-risking Gene Editing Targets for Hematopoietic Cell and Gene Therapy
2025Open Access
Cutting Through the Artifacts: Dissecting gRNA Impurities with FUSS-seq
2025Open Access
Integrating Human Genetics and Protective Genome Editing to Enable ADGRE2-Directed AML Therapy
2025Open Access
Multimodal Atlas of Paired Diagnosis and Relapse AML Reveals Surface Antigens for Multi-Specific Immunotherapy
Blood·2024Open Access
1092 Leveraging CRISPR/Cas9 and HDR to create an engineered CD33 CAR-T to treat AML
Regular and Young Investigator Award Abstracts·2024Open Access
Development of a gene edited next-generation hematopoietic cell transplant to enable acute myeloid leukemia treatment by solving off-tumor toxicity
Molecular Therapy — Methods & Clinical Development·2023· 3 citedOpen Access
Multimodal Atlas of Paired Diagnosis and Relapse AML Samples Enables Novel Therapeutic Targeting of Surface Antigens
Blood·2023· 1 citedOpen Access
CD33-Deleted Hematopoietic Cells (Trem-Cel) Are Protected from CD33xCD3 Bispecific Antibody Treatment and Produce Significantly Reduced Levels of Inflammatory Cytokines in Preclinical Studies
Blood·2023
260 Novel CLL-1-directed CAR-T cells mediate potent antigen-specific cytolytic activity in mouse models of acute myeloid leukemia
Regular and Young Investigator Award Abstracts·2023Open Access
Development of a gene edited next-generation hematopoietic cell transplant to enable acute myeloid leukemia treatment by solving off-tumor toxicity
Molecular Therapy — Methods & Clinical Development·2023· 16 citedOpen Access
Molecular and Functional Investigation of Human Hematopoietic Stem Cells during in Vitro Culture Supports a Novel Enrichment Strategy for Cell Manufacturing
Transplantation and Cellular Therapy·2023Open Access
Efficient Multiplex Gene Editing of CD33 and CLL-1 in Human Hematopoietic Stem Cells Enables the Potential of Next-Generation Transplants for AML Treatment
Blood·2022
Longitudinal Multimodal Atlas of AML Surface Antigens Enables Adaptive and Combinatorial Targeting
Blood·2022
miR-142 favors naïve B cell residence in peripheral lymph nodes
Frontiers in Immunology·2022· 4 citedOpen Access
334 Functional validation of single domain antibody-derived CD33 specific CAR-T cells for the treatment of acute myeloid leukemia
Regular and Young Investigator Award Abstracts·2022· 1 citedOpen Access
G-CSF/Plerixafor Dual-Mobilized Donor Derived CD33CAR T-Cells As Potent and Effective AML Therapy in Pre-Clinical Models
Blood·2021· 3 cited
Multiplex Engineering of Human CD34+ HSPCs Enables Dual Gene Knock-out While Maintaining High Engraftment Potential and Safety
Blood·2021
Knock out of CD123 or CLL-1 By CRISPR-Cas9 Editing from Human Hematopoietic Stem Cell Transplants Provide New Possibilities for Increasing Therapeutic Index and Safety for AML Treatment
Blood·2021· 1 cited
Sensitivity kernels for inferring Lorentz stresses from normal-mode frequency splittings in the Sun
arXiv (Cornell University)·2020Open Access
Context-specific regulation of cell survival by a miRNA-controlled BIM rheostat
Genes & Development·2019· 18 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

John R. Lydeard(14), Julia Etchin(11), Amanda L. Halfond(10), Yonina Keschner(10), Michelle I. Lin(9), Julian Scherer(8), Klaus Rajewsky(7), Ranjan Sen(6), Huanying Gary Ge(6), Michael A. Pettiglio(6), Mariana Silva(6), Matthew Ung(6), Gabriella Angelini(5), Jessica Lisle(5), Jianxin Hu(5), Elizabeth J. Paik(5), Guy Mundelboim(5), Ramesh Subrahmanyam(4), Ирина Иванова(4), Alfica Sehgal(4)